Introduction 27
Equine hoof canker (Pododermatitis chronica verrucosa s. migrans) is a destructive hypertrophic 28 pododermatitis of the frog, hoof wall and adjacent structures in equids. The disease is diagnosed by 29 its typical clinical appearance: filamentous or cauliflower-like proliferation of the hoof matrix with 30 foul smell and white cheesy exsudate. It is a sporadic chronic disorder, and at later stages it 31 compromises the use and welfare of horses. The disease often shortens lifetime of affected animals, 32 as therapy is often insufficient (Wilson and others; 1989 , Stashak, 2002 Dietz, 2006; Knottenbelt, 33 2009 ). It is likely that infection and an underlying defect in horn production are involved 34 (Knottenbelt, 2009 ), but several attempts to identify causative agents have been unsuccessful 35 (Turner, 1989 , Lacerda Neto and others, 2001 , Jongbloets and others, 2005 Brandt and others, 36 2010) . Surgical debridement of canker lesions in combination with a variety of topical formulations 37 are common treatment protocols (Wilson, 1994; Dietz, 2006; Stashak, 2002; O'Grady and Madison, 38 2004; Fürst and Lischer, 2006) , also combined with prednisolone (Oosterlinck and others, 2011) . If at 39 all successful, horses which recover often show short to medium term recurrence of the problem. 40
In a recent study sarcoid-inducing viral DNA and RNA of bovine papillomaviruses of types 1 and 2 41 (Brandt and others, 2010) have been detected in 24/24 canker tissue samples as well as in intact skin 42 and peripheral blood mononuclear cells of affected horses, whereas no viral DNA was detected in 43 horses without canker lesions. Also, clinical and histological similarities to equine sarcoids have been 44 observed (Rooney and Robertson, 1996) . Cisplatin is one of the most potent chemotherapy agents 45 used in human and veterinary medicine and intralesional cisplatin chemotherapy with and without 46 surgery is a well-documented and successful therapy for equine sarcoids (Hewes and Sullins, 2006; 47 Theon and others, 2007; Tamzali and others, 2011) . This paper documents a new and promising 48 therapy for canker with topical cisplatin chemotherapy aimed at a reduction of hospitalisation period 49 and short term recurrence. 50 51
Materials and Methods 53 54
Ten horses (see Table 1 ), admitted to the Equine Clinic of the Veterinary University Vienna from May 55 2011 to October 2012 for treatment of canker, were included in the study (Table 1 ). The disease was 56 diagnosed by its typical clinical appearance (Figure 1 ). A total of 19 hooves were affected, 13 front 57 and 9 hind hooves. 58
On day of hospitalisation affected hooves were trimmed, thoroughly cleaned and kept in disinfectant 59 bandages until surgery, which was between 1 and 4 days later. Using a tourniquet, affected 60 epidermal and dermal tissues were surgically debrided under regional anaesthesia. Two to six days 61 later, if healthy granulation tissue in the absence of any tissue suspicious of canker, topical cisplatin 62 chemotherapy was started. This included 10 applications of cisplatin paste (5ml Cisplatin injection 63 solution (1mg/ml), 5g EucillinB crème, Metronidazole-saccharose (125g) qs fiat pasta) on the surgical 64 wounds every other day. Treated hooves were bandaged until superficially keratinised or shod with a 65 treatment plate. During chemotherapy including 2 days after the last cisplatin application horses 66 were kept in isolation from other horses and unauthorized persons. Bandages were changed in a 67 dedicated treatment stable under strict precautions to prevent skin and eye contact of treating 68 personnel with cisplatin. 69
Results 71
All horses showed typical clinical signs of canker. In two horses small areas of tissue suspicious of 72 canker had to be removed after surgical debridement prior to the beginning of cisplatin 73 chemotherapy. In two horses some suspicious tissue had to be removed after the 5th cisplatin 74 treatment. Due to bleeding the treatment interval was three days on one of these occasions. 75
Wounds healed without complications (Figure 1 ). Mean hospitalisation for each cisplatin treatment 76 was 32.1 days (26 -39 days) ( Table 1) . Four horses were shod with a treatment plate, because 77 surgical wounds were not fully keratinized at the time of discharge. Horse 5 was hospitalised longer 78 on special request of owners who could not manage to change treatment plates at home. Follow up-79 information was obtained for all horses between 0 and 14 months and one horse developed a 80 recurrence 13 months after discharge (Table 1) The lack of a causative and successful therapy of equine hoof canker often leads to euthanasia of 85 affected animals (Wilson and others; 1989 , Stashak, 2002 Dietz, 2006; Knottenbelt, 2009) . 86 Canker therapy has been described as very time-consuming, requiring several months or more (Dietz, 87 2006; Fürst and Lischer, 2006; Knottenbelt, 2009 ). This could be markedly reduced with the 88 described topical cisplatin chemotherapy. After debridement, hypertrophic growth was easily 89 controlled in this study, which is in contrast to our own previous experience as well as previous 90 reports ( Knottenbelt, 2009) . During the follow-up period a low incidence of short to medium term 91 recurrence was noted in this study, although high recurrence rates, commonly within 12 months, are 92 described with established treatments (Oosterlinck and others, 2011). The horse that developed a 93 recurrence 13 months after discharge from clinic had undergone quite radical and intensive 94 treatments before the start of cisplatin chemotherapy and all its hooves were severely affected. This 95 agrees with reports, describing a reduced prognosis for extensive lesions for which adequate 96 treatment was delayed both for canker (Wilson, 1994; Stashak, 2002; Oosterlinck and others, 2011) 97 and sarcoids (Hewes and Sullins, 2006; Theon and others, 2007; Tamzali and others, 2011) . In 98 contrast to other cancer treatments, topical cisplatin chemotherapy appears to be cost-effective with 99 reduced hospitalisation time and reduced short to medium term recurrence rates. As such, repeated 100 treatments may also be feasible in horses with recurring canker lesions. 101
No local or systemic side effects of cisplatin were noticed in treated horses; however, health and 102 safety guidelines required strict precautionary measures to protect treating personnel from skin orDNA in canker, the apparent success of topical cisplatin chemotherapy also underlines the similarity 106 to equine sarcoids. 
